On the public citation graph

Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers)

0 signed · 44 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinternmed.2011.89openalex-extracted
The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
inferredcites →https://doi.org/10.1002/pds.2014openalex-extracted
Selected control events and reporting odds ratio in signal detection methodology
inferredcites →https://doi.org/10.1002/pds.668openalex-extracted
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
inferredcites →https://doi.org/10.1002/pds.677openalex-extracted
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
inferredcites →https://doi.org/10.1007/s11096-022-01425-4openalex-extracted
Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)
inferredcites →https://doi.org/10.1007/s40264-013-0048-4openalex-extracted
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
inferredcites →https://doi.org/10.1007/s40264-013-0116-9openalex-extracted
Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database
inferredcites →https://doi.org/10.1007/s40266-015-0318-1openalex-extracted
Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy
inferredcites →https://doi.org/10.1016/j.cell.2010.06.011openalex-extracted
Cell Signaling by Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/j.clinre.2012.10.003openalex-extracted
Crizotinib-induced acute hepatitis: First case with relapse after reintroduction with reduced dose
inferredcites →https://doi.org/10.1016/j.critrevonc.2019.02.006openalex-extracted
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.ejca.2019.05.032openalex-extracted
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
inferredcites →https://doi.org/10.1016/j.ejim.2021.10.035openalex-extracted
Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management
inferredcites →https://doi.org/10.1016/j.lungcan.2014.09.011openalex-extracted
Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells
inferredcites →https://doi.org/10.1016/j.lungcan.2015.12.010openalex-extracted
Crizotinib-induced fatal fulminant liver failure
inferredcites →https://doi.org/10.1016/j.lungcan.2017.06.004openalex-extracted
Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer
inferredcites →https://doi.org/10.1016/s0140-6736(17)30123-xopenalex-extracted
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
inferredcites →https://doi.org/10.1016/s1470-2045(17)30339-xopenalex-extracted
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
inferredcites →https://doi.org/10.1038/nature05945openalex-extracted
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/nrc3580openalex-extracted
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
inferredcites →https://doi.org/10.1038/s41586-021-04140-8openalex-extracted
Mechanism for the activation of the anaplastic lymphoma kinase receptor
inferredcites →https://doi.org/10.1038/sj.onc.1200849openalex-extracted
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
inferredcites →https://doi.org/10.1053/j.gastro.2019.02.002openalex-extracted
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
inferredcites →https://doi.org/10.1056/nejmoa1214886openalex-extracted
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1311107openalex-extracted
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1093/jjco/hyu086openalex-extracted
Fulminant Hepatitis Following Crizotinib Administration for ALK-positive Non-small-cell Lung Carcinoma
inferredcites →https://doi.org/10.1097/cad.0000000000000787openalex-extracted
Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines
inferredcites →https://doi.org/10.1097/md.0000000000013726openalex-extracted
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer
inferredcites →https://doi.org/10.1136/esmoopen-2019-000548openalex-extracted
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
inferredcites →https://doi.org/10.1159/000521452openalex-extracted
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1186/s12890-020-01390-6openalex-extracted
Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
inferredcites →https://doi.org/10.1200/jgo.2016.007765openalex-extracted
Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event
inferredcites →https://doi.org/10.1242/jcs.01183openalex-extracted
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
inferredcites →https://doi.org/10.12998/wjcc.v7.i9.1080openalex-extracted
Crizotinib-induced acute fatal liver failure in an Asian ALK-positive lung adenocarcinoma patient with liver metastasis: A case report
inferredcites →https://doi.org/10.1517/14740338.4.5.929openalex-extracted
The role of data mining in pharmacovigilance
inferredcites →https://doi.org/10.1530/jme-11-0004openalex-extracted
Anaplastic lymphoma kinase in human cancer
inferredcites →https://doi.org/10.1586/era.13.18openalex-extracted
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
inferredcites →https://doi.org/10.2147/cmar.s190098openalex-extracted
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
inferredcites →https://doi.org/10.2165/00002018-200225060-00001openalex-extracted
Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database
inferredcites →https://doi.org/10.3109/10520295.2012.758311openalex-extracted
Serum IGF-1 levels correlate negatively to liver damage in diabetic rats
inferredcites →https://doi.org/10.3389/fimmu.2022.778635openalex-extracted
Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years
inferredcites →https://doi.org/10.3389/fphar.2022.858279openalex-extracted
Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
inferredcites →https://doi.org/10.3747/co.21.1740openalex-extracted
Managing Treatment–Related Adverse Events Associated with Alk Inhibitors
inferredcites →https://doi.org/10.3748/wjg.v10.i18.2740openalex-extracted
Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.